Stockreport

NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses

NovaBay Pharmaceuticals, Inc.  (NBY) 
NASDAQ:AMEX Investor Relations: novabay.com/investors
PDF Growth driven by efficient Avenova® direct-to-consumer e-marketing programs EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) r [Read more]